Acceleron Pharma Inc (NASDAQ:XLRN) has received a consensus rating of “Buy” from the fourteen research firms that are presently covering the firm. Two research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $45.44.
Several equities research analysts have recently issued reports on the stock. Citigroup Inc raised shares of Acceleron Pharma from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $40.00 to $36.00 in a research report on Thursday, March 2nd. Cann reissued an “outperform” rating on shares of Acceleron Pharma in a research report on Wednesday, March 1st. Instinet assumed coverage on shares of Acceleron Pharma in a research report on Wednesday, March 1st. They set a “buy” rating and a $58.00 price objective for the company. Zacks Investment Research raised shares of Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Friday, February 10th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Acceleron Pharma in a research report on Tuesday, March 14th. They set a “neutral” rating and a $33.00 price objective for the company.
Acceleron Pharma (NASDAQ:XLRN) traded down 1.23% on Tuesday, reaching $28.02. 375,273 shares of the company’s stock traded hands. Acceleron Pharma has a 52-week low of $23.07 and a 52-week high of $41.69. The firm’s market capitalization is $1.08 billion. The firm’s 50 day moving average price is $27.79 and its 200 day moving average price is $28.87.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.04. Acceleron Pharma had a negative net margin of 229.77% and a negative return on equity of 30.75%. The company earned $3.37 million during the quarter, compared to the consensus estimate of $3.74 million. During the same quarter in the prior year, the firm earned ($0.81) earnings per share. The firm’s revenue was down 11.3% compared to the same quarter last year. On average, analysts predict that Acceleron Pharma will post ($2.27) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XLRN. Bessemer Group Inc. increased its position in Acceleron Pharma by 3,999.1% in the fourth quarter. Bessemer Group Inc. now owns 4,755 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 4,639 shares during the period. Tudor Investment Corp Et Al increased its position in Acceleron Pharma by 24.1% in the fourth quarter. Tudor Investment Corp Et Al now owns 8,389 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 1,631 shares during the period. Bank of Montreal Can acquired a new position in Acceleron Pharma during the first quarter worth $237,000. SG Americas Securities LLC acquired a new position in Acceleron Pharma during the third quarter worth $320,000. Finally, Russell Investments Group Ltd. acquired a new position in Acceleron Pharma during the fourth quarter worth $378,000. 82.57% of the stock is owned by institutional investors and hedge funds.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.